Literature DB >> 22160050

Complications, diagnosis, management, and prevention of CMV infections: current and future.

Michael Boeckh1.   

Abstract

Although major progress has been made in the prevention of CMV disease after hematopoietic cell transplantation (HCT), specific problems remain and available antiviral agents are associated with major toxicities. This article reviews current aspects of CMV diagnosis, prevention, and treatment in HCT recipients and defines areas of unmet medical need.

Entities:  

Mesh：

Year:  2011        PMID： 22160050     DOI： 10.1182/asheducation-2011.1.305

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  26 in total

1.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

2.  Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.

Authors:  Emilien Drouot; Jocelyne Piret; Marc H Lebel; Guy Boivin
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

3.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

4.  Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.

Authors:  Phaedon Zavras; Yiqi Su; Jiaqi Fang; Anat Stern; Nitasha Gupta; Yuexin Tang; Amit Raval; Sergio Giralt; Miguel Angel Perales; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-19       Impact factor: 5.742

5.  Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction?

Authors:  Nina Zidar; Ivan Ferkolj; Katja Tepeš; Borut Štabuc; Nika Kojc; Tina Uršič; Miroslav Petrovec
Journal:  Virchows Arch       Date:  2015-02-21       Impact factor: 4.064

6.  Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients.

Authors:  N Esther Babady; Cindy Cheng; Evelyn Cumberbatch; Jeffrey Stiles; Genovefa Papanicolaou; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

Review 7.  The Human Virome: Implications for Clinical Practice in Transplantation Medicine.

Authors:  Susanna K Tan; David A Relman; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

8.  Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.

Authors:  C S Link; A Eugster; F Heidenreich; E Rücker-Braun; M Schmiedgen; U Oelschlägel; D Kühn; S Dietz; Y Fuchs; A Dahl; A M J Domingues; C Klesse; M Schmitz; G Ehninger; M Bornhäuser; J Schetelig; E Bonifacio
Journal:  Clin Exp Immunol       Date:  2016-03-08       Impact factor: 4.330

9.  Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.

Authors:  T Bontant; P Sedlaçek; A Balduzzi; B Gaspar; S Cesaro; H Einsele; C Peters; J-H Dalle
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

10.  The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.

Authors:  E Oiknine-Djian; Y Weisblum; A Panet; H N Wong; R K Haynes; D G Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.